Putting Physics to Work in the Fight Against Cancer

Episode Summary

Executive Summary: The episode features Nanobiotics CEO Laurent Levy discussing how intratumoral nanoparticles can enhance radiation therapy by absorbing X-rays and amplifying damage inside cancer cells while sparing healthy tissue. He argues the approach could improve local control, potentially trigger immune responses, and be broadly applicable across cancers treated with radiation, with lead development in soft tissue sarcoma and head and neck cancer.

Main Topics: Why radiation therapy still matters in cancer care (Priority: 5/5): Levy explains that radiation remains widely used because many cancers begin as localized disease, but conventional radiation can damage healthy tissue while trying to kill tumors. Nanobiotics’ physics-based nanoparticle platform (Priority: 5/5): The company’s core technology uses ~50 nm nanoparticles injected directly into tumors before radiation to absorb X-rays and generate destructive electrons inside cancer cells. Clinical positioning and tumor applicability (Priority: 4/5): Levy says intratumoral delivery is intended to maximize local benefit and reduce systemic exposure, and that any biopsy-accessible tumor could potentially be treated with a one-time injection. Lead indications and pipeline priorities (Priority: 4/5): The company is prioritizing soft tissue sarcoma and head and neck cancer, especially frail elderly patients who may not tolerate standard chemoradiation. Safety and efficacy signals from trials (Priority: 5/5): Levy describes a favorable safety profile with no chronic toxicity seen so far and says early clinical data suggest promising efficacy, including a phase 3 randomized sarcoma study nearing readout. Potential immune and combination-therapy effects (Priority: 4/5): Beyond local tumor destruction, the platform may stimulate immune recognition of tumors and is being tested with checkpoint inhibitors and radiation in difficult-to-treat patients. Regulatory and commercialization plans (Priority: 3/5): Nanobiotics expects European approval in the coming months and is still defining its U.S. market strategy, including whether to commercialize alone or with a partner.

Key Arguments: Radiation is still a major cancer treatment because many patients first present with localized disease, and local control can prevent later metastasis. Conventional radiation is limited by collateral damage to surrounding healthy tissue, creating a need to increase tumor dose selectively. Intratumoral nanoparticles can amplify radiation locally by absorbing X-rays and generating high-energy electrons that destroy cancer cells. A one-time injection before radiation improves benefit-risk balance by concentrating treatment in the tumor and limiting systemic exposure. The platform may do more than create local destruction; it may also help the immune system recognize the tumor and contribute to systemic responses. The technology could be broadly used because any tumor that can be biopsied may be eligible for direct injection. Nanobiotics is prioritizing unmet need populations, including frail elderly head and neck cancer patients who cannot easily receive standard chemoradiation. Early trials suggest a strong safety profile, and the company believes the approach could change outcomes in immuno-oncology-resistant patients when combined with checkpoint inhibitors. Commercial adoption may be easier than for wholly new modalities because it fits within existing radiation oncology workflows without new equipment or major protocol changes.

Data Points: Approximate share of cancer patients receiving radiation: 50% - Levy says about half of all cancer patients receive some radiation therapy at some point. Nanoparticle size: ~50 nanometers - He describes the first metal particles as around fifty nanometers in diameter. Human hair comparison: ~3,000x smaller than hair diameter - He compares a 60 nm particle to a hair cut 3,000 times. Clinical trial count: More than 7 - Nanobiotics has conducted more than seven clinical trials. Patients enrolled in clinical trials: More than 200 - Levy says the company has enrolled more than 200 patients across trials. Sarcoma trial design: Phase 3 randomized trial - He says the lead soft tissue sarcoma program is in a phase 3 randomized study. Expected sarcoma readout: Q2 - He states data readout for the sarcoma study is expected in Q2 soon. European approval timeline: Within the coming months - Levy expects the first market approval in Europe soon. U.S. strategy timing: By summer - He says the company expects more clarity on its U.S. go-to-market plan by summer.

Pivotal Quotes: "we have developed some very small objects, nanoparticles, that are small enough to go into cells" — Laurent Levy: Explaining the core mechanism of the platform. "you insert a product within an existing medical practice that exists in every single hospital treating cancer with radiation threat" — Laurent Levy: Describing why adoption could be practical for clinicians. "this product could be one of these rare oncology products that will do all that in one very fast population" — Laurent Levy: Referring to potential benefits in frail head and neck cancer patients.

Implications: If the data hold up, Nanobiotics could offer a scalable way to boost radiation efficacy without rewriting oncology workflows. The approach may expand into multiple cancers and combination regimens, potentially improving outcomes in patients with limited options.